Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma

Br J Haematol. 2003 Oct;123(1):106-9. doi: 10.1046/j.1365-2141.2003.04561.x.


The role of serum macrophage inflammatory protein-1 alpha (MIP-1alpha) in bone disease and survival was evaluated in 85 newly diagnosed multiple myeloma (MM) patients. MIP-1alpha was elevated in MM patients and correlated with the extent of bone disease, bone resorption markers and levels of soluble receptor activator of nuclear factor-kappaB (RANK) ligand. MIP-1alpha was also associated with survival; the 3-year probability of survival was 85% and 44% for MIP-1alpha levels below and above 48 pg/ml respectively (P = 0.021). This suggests that MIP-1alpha contributes to the pathogenesis of bone disease in MM and possibly in tumour growth, as reflected by its impact on survival.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Bone Resorption
  • Carrier Proteins / blood
  • Chemokine CCL3
  • Chemokine CCL4
  • Female
  • Humans
  • Macrophage Inflammatory Proteins / blood*
  • Male
  • Membrane Glycoproteins / blood
  • Middle Aged
  • Multiple Myeloma / blood*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Probability
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Stem Cell Transplantation
  • Survival Rate


  • Biomarkers, Tumor
  • Carrier Proteins
  • Chemokine CCL3
  • Chemokine CCL4
  • Macrophage Inflammatory Proteins
  • Membrane Glycoproteins
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • TNFRSF11A protein, human
  • TNFSF11 protein, human